Adagrasib (Ada) plus cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.

被引：0

作者：

Yaeger, Rona

Uboha, Nataliya V.

Klempner, Samuel J.

Bekaii-Saab, Tanios S.

Sabari, Joshua K.

Barve, Minal A.

Saltzman, Joel N.

Peguero, Julio Antonio

Paulson, Andrew Scott

Janne, Pasi A.

Pelster, Meredith

Cruz-Correa, Marcia

Kim, Amy Min Kyung

Hu, Nan

Ahmad, Harris A.

Kopetz, Scott

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Mayo Clin Arizona, Phoenix, AZ USA

[5] Perlmutter Canc Ctr, New York, NY USA

[6] Mary Crowley Canc Res, Dallas, TX USA

[7] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[8] Oncol Consultants, Houston, TX USA

[9] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Sarah Cannon Res Inst, Nashville, TN USA

[12] PanOncol Trials, San Juan, PR USA

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.131

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：131 / 131

页数：1